

In the claims:

1-10. (canceled).

11. (currently amended). A method for the prophylaxis and/or treatment of breast, lung and/or pancreatic cancer in a subject, which comprises administering to said subject a therapeutically effective amount of an antibody which is a monoclonal, chimeric, humanised or completely human antibody, wherein said antibody specifically binds to a NKCC1 polypeptide which consists of the amino acid sequence of SEQ ID NO: 1 as defined in claim 6.

12-27. (canceled)

28. (new). The method according to claim 11, wherein the antibody is conjugated to a detectable substance, a therapeutic moiety, or a cytotoxic agent.

29. (new). The method according to claim 11, wherein the antibody is a Fab fragment or F(ab')2 fragment.

30. (new). The method according to claim 28, wherein the antibody is a Fab fragment or F(ab')2 fragment.